



CERTARA[®]
Drug Interaction
Database (DIDB[®])

Optimize DDI
Knowledge
throughout Drug
Development

CERTARA[®]

Streamline scientific evaluation of drug interactions and safety

Curated daily by a team of research scientists with extensive expertise in drug-drug interactions (DDIs) and pharmacogenetics to maintain a high degree of accuracy, DIDB® enables informed decision-making related to the evaluation of pharmacokinetic (PK) based drug interactions and safety. A user-friendly interface with pre-formulated query options allows users to efficiently retrieve up-to-date information from a large body of publications and regulatory documentation.

Get more value out of your DIDB license

Certara DDI experts empower pharmaceutical researchers and regulatory scientists to decode complex drug interactions. By leveraging the scientist-curated DIDB and our team's extensive expertise, we deliver actionable insights to improve clinical decision-making and ensure patient safety. Our services include literature and NDA reviews, mechanistic assessments, and evaluations of PK variability to guide study designs and optimize therapeutic outcomes.

Why Choose Certara's DIDB?

200+

pharmaceutical companies, academic institutions, regulatory agencies, CROs and non-profit groups worldwide trust DIDB

27K

citations from all relevant publications and FDA regulatory documents

210K

entries and coupling

1,750

list of drug interaction characteristics include substrates, inhibitors, and inducers for enzymes (CYPs and UGTs) and transporters (P-gp, BCRP, OATP1B1/3, OAT 1/3, OCT2, MATE1/2-K), classified based on DDI and pharmacogenetic data

23K

compounds including marketed drugs, drugs under clinical investigations, herbal and natural products, food products, etc.

resmetirom [PubChem](#) [Print / Save as PDF](#)

NDA 217785 **77 entries** [RI Study](#) [HI Study](#) [Food-Effect Study](#) approval year: 2024

Therapeutic class	Miscellaneous Agents — Other
Brand name	REZDIFFRA (tablets)
Indications and usage	REZDIFFRA is a thyroid hormone receptor-beta (THR-beta) agonist indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Clinical recommended dosage	80 mg (actual body weight < 100 kg) or 100 mg (actual body weight ≥ 100 kg) orally once daily with or without food
Molecular weight	435.22 g/mol
Biopharmaceutics class	Class IV: Low permeability - Low solubility reference: NDA# 217785 Chemistry Review

Synonyms: MGL-3196

resmetirom

- General information
- Characteristics
- Pharmacokinetic profile
- DDI summary
 - Main routes of elimination
 - Main enzymes and associated interactions
 - Main transporters and associated interactions
- Inhibition profile
- Induction profile
- Other DDIs
- QT summary
- Relationship to other compounds
- External resources

Chemical structure: CC1=CC(=C(C=C1)C2=CC(=C(C=C2)OC3=CC(=C(C=C3)N4C(=O)NC(=O)N4C#N)C5=CC(=C(C=C5)Cl)Cl

Figure 1. DIDB's in-depth monographs summarize a drug's main mechanistic and quantitative findings.

Explore DIDB's dynamic research tools and applications

Retrieve information using 70+ pre-formulated queries

Search the DIDB with multiple query options like therapeutic class, enzyme, transporter, gene name, *in vitro* parameter and PK parameter.

Optimize and validate PBPK models and static predictions

Use query results to guide input parameter selection and provide context for results obtained for candidate compounds.

Support drug labeling recommendations

Improve context of DDI information contained on drug labels to promote the safe use of medications in various patient populations.

Calculate clinical DDI risk using static prediction model and generate submission-ready reports

The DDI Calculator helps scientists explore the clinical DDI risk of a compound acting as a precipitant or perpetrator based on the compound properties and early *in vitro* results.


De-risk DDI management during clinical trials

Quickly identify concomitant medications that are contraindicated, require dose adjustments or need monitoring during a trial using DIDB's Concomitant Meds Navigator.

The industry's largest scientist-curated database for assessing drug interactions and safety

Continuously updated

Database is updated daily, and in-house scientists with extensive DDI and pharmacogenetics expertise analyze 100+ peer-reviewed publications and several NDA/BLA packages monthly.



Gain insights beyond DDIs

DIDB goes beyond drug interaction with drugs, offering comprehensive information on various extrinsic and intrinsic factors that influence drug exposure.

Easily accessible

Common metrics used across all studies to allow metadata analysis of quantitative results. Results can be viewed, customized, and downloaded in multiple formats, allowing users to compile and organize the large body of available information.



"DIDB is an amazing resource. It streamlines our research of pharmacokinetic parameters for individual drugs and has cut down our time to evaluate a medication by at least 50%. The team there is responsive to questions, and they have a nice training program to orient you to the tool. The ability to filter drug data in a seemingly infinite number of ways is a key feature."

Senior Vice President of Medical Affairs
Pharmacogenetics & Personalized Medicine
Service Provider, USA

Learn more about the DIDB® platform
and schedule a demo

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.

Visit certara.com | Copyright ©2025 Certara. All rights reserved.

CERTARA®